Gnubiotics Sciences
Gnubiotics is a biotechnology company focused on developing novel glycopeptide therapeutics to address unmet medical needs in oncology and other diseases. Their proprietary GENESIS platform synergizes glycopeptides, CMC, evolutionary systems biology, and generative AI to design targeted therapies. Their lead candidate, GNU101, is a glycopeptide therapeutic designed to break through immuno-oncology (I/O) resistant cancers by activating the immune system. The platform also targets chronic inflammation, microbiome modulation, and metabolic syndrome. Gnubiotics is advancing its lead candidate towards IND approval and phase 1 trials, collaborating with academic medical centers. The company emphasizes the rational design and manufacturing of precise complex glycopeptide biologics with a strong safety profile.
Gnubiotics Sciences
Gnubiotics is a biotechnology company focused on developing novel glycopeptide therapeutics to address unmet medical needs in oncology and other diseases. Their proprietary GENESIS platform synergizes glycopeptides, CMC, evolutionary systems biology, and generative AI to design targeted therapies. Their lead candidate, GNU101, is a glycopeptide therapeutic designed to break through immuno-oncology (I/O) resistant cancers by activating the immune system. The platform also targets chronic inflammation, microbiome modulation, and metabolic syndrome. Gnubiotics is advancing its lead candidate towards IND approval and phase 1 trials, collaborating with academic medical centers. The company emphasizes the rational design and manufacturing of precise complex glycopeptide biologics with a strong safety profile.